葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002737 葵花药业

已收盘 05-12 15:00:00

{"stockData":{"symbol":"002737","market":"SZ","secType":"STK","nameCN":"葵花药业","latestPrice":16.06,"timestamp":1747033413000,"preClose":15.98,"halted":0,"volume":3344300,"delay":0,"changeRate":0.005,"floatShares":584000000,"shares":584000000,"eps":0.5034,"marketStatus":"已收盘","change":0.08,"latestTime":"05-12 15:00:00","open":16.02,"high":16.07,"low":15.91,"amount":53484800,"amplitude":0.01,"askPrice":16.06,"askSize":531,"bidPrice":16.05,"bidSize":1258,"shortable":0,"etf":0,"ttmEps":0.5034,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747099800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.98,"symbolType":"stock","openAndCloseTimeList":[[1747013400000,1747020600000],[1747026000000,1747033200000]],"highLimit":17.58,"lowLimit":14.38,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":584000000,"isCdr":false,"pbRate":2.1,"roa":"--","peRate":31.903059,"roe":"1.3%","epsLYR":0.84,"committee":-0.011219,"marketValue":9379000000,"turnoverRate":0.0057,"status":0,"floatMarketCap":9379000000},"requestUrl":"/m/hq/s/002737","defaultTab":"news","newsList":[{"id":"2533097121","title":"葵花药业最新公告：控股孙公司双醋瑞因胶囊获得上市许可受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533097121","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533097121?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:12","pubTimestamp":1746695527,"startTime":"0","endTime":"0","summary":"葵花药业(002737.SZ)公告称，控股孙公司葵花药业集团湖北武当有限公司于近日收到国家药品监督管理局下发的关于双醋瑞因胶囊申请注册上市许可的《受理通知书》。该产品拟定适应症为用于髋、膝关节的骨关节炎治疗。不过，药品审评周期长、环节多，具体完成时间、审批结果存在不确定性。公司将积极推进该产品的上市许可工作并持续关注审批情况，及时履行信息披露义务。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050800023968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"gpt_icon":0},{"id":"2533971870","title":"葵花药业：医疗健康产业的需求仍处于上升通道","url":"https://stock-news.laohu8.com/highlight/detail?id=2533971870","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533971870?lang=zh_cn&edition=full","pubTime":"2025-05-08 17:08","pubTimestamp":1746695310,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK0239","002737","159760","BK0028"],"gpt_icon":0},{"id":"2533975828","title":"葵花药业(002737.SZ)：双醋瑞因胶囊获得上市许可受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2533975828","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533975828?lang=zh_cn&edition=full","pubTime":"2025-05-08 16:32","pubTimestamp":1746693124,"startTime":"0","endTime":"0","summary":"智通财经APP讯，葵花药业(002737.SZ)发布公告，公司控股孙公司葵花药业集团湖北武当有限公司于近日收到国家药品监督管理局下发的关于双醋瑞因胶囊申请注册上市许可的《受理通知书》。上述药品在获国家药品监督管理局注册上市许可申请受理后，将转入国家药品监督管理局药品审评中心进行审评审批，鉴于药品审评周期长、环节多，期间可能受不确定性因素影响，具体完成时间、审批结果存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"葵花药业(002737.SZ)：双醋瑞因胶囊获得上市许可受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2533672034","title":"葵花药业(002737)4月18日股东户数5.4万户，较上期减少1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2533672034","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533672034?lang=zh_cn&edition=full","pubTime":"2025-05-07 17:16","pubTimestamp":1746609374,"startTime":"0","endTime":"0","summary":"证券之星消息，近日葵花药业披露，截至2025年4月18日公司股东户数为5.4万户，较3月31日减少1081.0户，减幅为1.96%。在中药行业个股中，葵花药业股东户数高于行业平均水平，截至4月18日，中药行业平均股东户数为5.22万户。从股价来看，2025年3月31日至2025年4月18日，葵花药业区间跌幅为5.59%，在此期间股东户数减少1081.0户，减幅为1.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700026168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"gpt_icon":0},{"id":"2533624265","title":"葵花药业：截至2025年4月18日，公司股东人数为5.4万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2533624265","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533624265?lang=zh_cn&edition=full","pubTime":"2025-05-07 15:09","pubTimestamp":1746601758,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)05月07日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！请问截止到2025年04月20日止贵公司持股股东户数是多少？谢谢！葵花药业回复：截至2025年4月18日，公司股东人数为5.4万人，感谢关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025050700017575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002737"],"gpt_icon":0},{"id":"2531352940","title":"葵花药业财报解读：双品牌驱动产品精准布局 高比例分红彰显发展信心","url":"https://stock-news.laohu8.com/highlight/detail?id=2531352940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531352940?lang=zh_cn&edition=full","pubTime":"2025-04-30 19:37","pubTimestamp":1746013036,"startTime":"0","endTime":"0","summary":"近日，葵花药业披露2024年年度报告。合同负债显著增加 高比例分红彰显信心 观察葵花药业的这份年报可知，公司在多因素影响下，业绩短期承压。在儿童用药品牌“小葵花”与“葵花”成人用药品牌双品牌的驱动下，葵花药业正在用自身的精准布局，取得更加广阔的市场份额。作为一家品牌 OTC 企业，葵花药业重视品牌建设及打造，目前，葵花成人药品牌家喻户晓，小葵花儿童药品牌已成为行业领导品牌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025043000042160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737"],"gpt_icon":0},{"id":"2530146053","title":"【机构调研记录】诺德基金调研奥特维、葵花药业等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2530146053","media":"证星机构调研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530146053?lang=zh_cn&edition=full","pubTime":"2025-04-28 08:03","pubTimestamp":1745798594,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及4月25日披露的机构调研信息，诺德基金近期对6家上市公司进行了调研，相关名单如下：1）奥特维 个股亮点：公司目前应用于半导体封测环节的设备有划片机、铝线键合机、AOI检测设备等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280814049747b995&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280814049747b995&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0028","BK0251","002737","688516","BK0239"],"gpt_icon":0},{"id":"2530460533","title":"【私募调研记录】正圆投资调研葵花药业、青达环保等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2530460533","media":"证星私募调研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530460533?lang=zh_cn&edition=full","pubTime":"2025-04-28 08:00","pubTimestamp":1745798458,"startTime":"0","endTime":"0","summary":"5）当升科技 个股亮点：公司持有蓝谷智慧股权比例为2.54%，标的业务所涉及的电池回收及电池梯次利用等；公司是锂电池正极材料领域的龙头企业，其高镍三元材料广泛应用于新能源汽车动力电池。机构简介：深圳正圆投资2015年成立于深圳前海自贸区，并于当年获得私募证券投资基金牌照。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280804449747b722&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504280804449747b722&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688501","002737","BK0028","BK0251","BK0239"],"gpt_icon":0},{"id":"2530331460","title":"【私募调研记录】明汯投资调研葵花药业、太极集团","url":"https://stock-news.laohu8.com/highlight/detail?id=2530331460","media":"证星私募调研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530331460?lang=zh_cn&edition=full","pubTime":"2025-04-28 08:00","pubTimestamp":1745798452,"startTime":"0","endTime":"0","summary":"投资范围涵盖股票、期货、期权等。明汯投资业务涵盖市场分析、策略开发、资产配置、风险管理及系统开发。明汯深耕量化投资领域，是目前国内在金融衍生品投资领域兼具国际视野、精深研究、完备团队和丰富实战的量化投资机构之一，并且积极吸收和引进全球领先金融机构在量化投资领域的成熟经验和技术，结合中国市场的实际情况，探索和研究适合中国资本市场特色的量化投资策略、研究体系、风控体系和交易体系。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042808041994e51a90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042808041994e51a90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002737","BK0239","600129","BK0028","BK0113"],"gpt_icon":0},{"id":"2529676386","title":"葵花药业：公司主营产品包括成人用药和儿童用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2529676386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529676386?lang=zh_cn&edition=full","pubTime":"2025-04-24 17:00","pubTimestamp":1745485234,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业04月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好我想问一下管理层是否打算发展成人用药，我了解到贵公司聚焦小儿用药，24年报净利润也在下滑，可能是竞争加剧和需求减少导致的，如果成人用药有了代表产品或许会加快估值修复葵花药业回复：公司主营产品包括成人用药和儿童用药，其中，成人用药领域产品已涵盖消化系统、呼吸感冒系统、风湿骨病系统、心脑血管系统、妇科、补益及健康领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400028348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002737","BK0239","BK0028"],"gpt_icon":0},{"id":"2514052031","title":"葵花药业：截至2025年2月20日，公司股东人数为5.43万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2514052031","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514052031?lang=zh_cn&edition=full","pubTime":"2025-02-25 16:30","pubTimestamp":1740472243,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)02月25日在投资者关系平台上答复投资者关心的问题。投资者：请问贵公司董秘，截止2月20日，股东人数有多少，谢谢！！！葵花药业董秘：截至2025年2月20日，公司股东人数为5.43万人。感谢关注。投资者：公司的小葵花大药房是走线上模式，还是线上线下一起，具体在全国哪些省份会布局线下药店？葵花药业董秘：公司设立葵花大药房（湖北）有限公司，旨在顺应数字营销趋势，打造线上自营平台，以构建线上营销业务闭环管理。感谢关注。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025022500028338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2505768780","title":"葵花药业：截至2025年1月20日，公司股东人数为5.27万人","url":"https://stock-news.laohu8.com/highlight/detail?id=2505768780","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505768780?lang=zh_cn&edition=full","pubTime":"2025-01-22 12:00","pubTimestamp":1737518449,"startTime":"0","endTime":"0","summary":"证券之星消息，葵花药业(002737)01月21日在投资者关系平台上答复投资者关心的问题。投资者：请问董事会秘书截止1月20号收盘，股东人数是多少？谢谢！葵花药业董秘：截至2025年1月20日，公司股东人数为5.27万人。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012200018512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"gpt_icon":0},{"id":"2505753107","title":"葵花药业（002737）1月21日主力资金净卖出7268.51万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505753107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505753107?lang=zh_cn&edition=full","pubTime":"2025-01-22 09:23","pubTimestamp":1737509037,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月21日收盘，葵花药业报收于18.17元，下跌2.57%，换手率2.0%，成交量11.68万手，成交额2.14亿元。近5日资金流向一览见下表：葵花药业融资融券信息显示，融资方面，当日融资买入1771.59万元，融资偿还3568.48万元，融资净偿还1796.89万元。葵花药业主营业务：各类中成药、化学药品的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012200009465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002737","BK0028"],"gpt_icon":0},{"id":"2505561216","title":"葵花药业利润预计下降！研发费用连续提升、打造多品牌IP助力竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2505561216","media":"大消费之家","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505561216?lang=zh_cn&edition=full","pubTime":"2025-01-21 12:13","pubTimestamp":1737432780,"startTime":"0","endTime":"0","summary":"业绩利润率双降，研发费用连续提升从葵花药业2024年公布的各季度财报数据来看，其业绩表现似乎不容乐观。其中2024年第一季度，公司营业收入15.18亿元，同比下降14.01%；归母净利润2.55亿元，同比下降37.17%。中药原材料价格在近年来保持高位运行，给葵花药业带来了不小的成本压力。这些投诉事件虽看似零星孤立，却可能对葵花药业的品牌形象和消费者信任度造成潜在的、不可忽视的冲击。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-01-21/doc-ineftfic8093634.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK0028","BK4136","002737","IP","LU2463526074.USD","BK0239","BK4588"],"gpt_icon":0},{"id":"2504473370","title":"1月20日葵花药业跌5.67%，大成优选升级一年持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2504473370","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504473370?lang=zh_cn&edition=full","pubTime":"2025-01-20 16:16","pubTimestamp":1737361005,"startTime":"0","endTime":"0","summary":"证券之星消息，1月20日葵花药业跌5.67%创60日新低，收盘报18.65元，换手率3.41%，成交量19.91万手，成交额3.69亿元。重仓葵花药业的公募基金请见下表：根据2024基金Q3季报公募基金重仓股数据，重仓该股的公募基金共7家，其中持有数量最多的公募基金为大成优选升级一年持有混合A。大成优选升级一年持有混合A目前规模为2.63亿元，最新净值0.8917，较上一交易日上涨0.55%，近一年上涨6.73%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025012000020110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002737","BK0239"],"gpt_icon":0},{"id":"2504139553","title":"葵花药业（002737）1月17日主力资金净流出596.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504139553","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504139553?lang=zh_cn&edition=full","pubTime":"2025-01-17 17:34","pubTimestamp":1737106476,"startTime":"0","endTime":"0","summary":"金融界消息 截至2025年1月17日收盘，葵花药业报收于19.77元，上涨0.87%，换手率0.79%，成交量4.60万手，成交金额9068.55万元。资金流向方面，今日主力资金净流出596.86万元，占比成交额6.58%。葵花药业最新一期业绩显示，截至2024三季报，公司营业总收入29.67亿元、同比减少29.95%，归属净利润5.87亿元，同比减少31.06%，扣非净利润4.60亿元，同比减少42.05%，流动比率3.998、速动比率3.049、资产负债率20.79%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/17173447558767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["002737","BK0239","BK0028"],"gpt_icon":0},{"id":"2501867721","title":"泻立停被全面禁售！","url":"https://stock-news.laohu8.com/highlight/detail?id=2501867721","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501867721?lang=zh_cn&edition=full","pubTime":"2025-01-08 20:30","pubTimestamp":1736339400,"startTime":"0","endTime":"0","summary":"1月8日，#泻立停被全面禁售#冲上热搜。已上市销售的产品，由药品上市许可持有人负责召回，召回产品由所在地省级药品监督管理部门监督销毁或者依法采取其他无害化处理等措施。北京医院药学部主任药师金鹏飞表示，泻立停里所含的磺胺类和颠茄类成分，相对来讲，安全性并不很高，且不良反应也较多。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2025-01-08/doc-ineehmtv3872612.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2025-01-08/doc-ineehmtv3872612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0070","600750","BK0188","002262","BK0028","BK0191","BK0239","002737","BK0175","600812"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1747047445957,"stockEarnings":[{"period":"1week","weight":0.0185},{"period":"1month","weight":-0.0561},{"period":"3month","weight":-0.1225},{"period":"6month","weight":-0.2441},{"period":"1year","weight":-0.4259},{"period":"ytd","weight":-0.2201}],"compareEarnings":[{"period":"1week","weight":0.0192},{"period":"1month","weight":0.0487},{"period":"3month","weight":0.0116},{"period":"6month","weight":-0.0319},{"period":"1year","weight":0.0595},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"葵花药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"54000人(较上一季度减少1.96%)","perCapita":"10814股","listingDate":"2014-12-30","address":"黑龙江省哈尔滨市道里区高新技术产业开发区迎宾路集中区东湖路18号","registeredCapital":"58400万元","survey":"　　葵花药业集团股份有限公司主营业务以生产中成药为主导,以“化学药、生物药”和“健康养生品”为两翼,是集药品研发、制造与营销为一体的大型品牌医药集团企业。公司主要产品涵盖呼吸感冒系统用药、消化系统用药、风湿骨病用药、心脑血管用药、妇科用药、补益用药及健康产品。公司荣登2023中国医药工业发展大会-2022年度中国医药工业百强榜，获评2023中国医药工业发展大会2023年中国医药工业最具投资价值，2023中国经济高峰论坛暨第二十一届中国经济人物年会－2023中国上市公司品牌500强。","listedPrice":36.53},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"葵花药业,002737,葵花药业股票,葵花药业股票老虎,葵花药业股票老虎国际,葵花药业行情,葵花药业股票行情,葵花药业股价,葵花药业股市,葵花药业股票价格,葵花药业股票交易,葵花药业股票购买,葵花药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"葵花药业(002737)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供葵花药业(002737)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}